Clinical Trial Update: Bevacizumab in Treating Patients Who Have Undergone First-Line Therapy for Metastatic Colorectal Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial update for bevacizumab in metastatic colorectal cancer after first-line therapy has terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: Swiss Cancer Institute | Conditions: Colorectal Cancer | Phase 3 | Status: TERMINATED